Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload

Haematologica

Volumn 96, Issue 1, 2011, Pages 48-54

  Pennell, Dudley J ^a   Porter, John B ^b   Cappellini, Maria Domenica ^c   Chan, Lee Lee ^d   El Beshlawy, Amal ^e   Aydinok, Yesim ^f   Ibrahim, Hishamshah ^g   Li, Chi Kong ^h   Viprakasit, Vip ⁱ   Elalfy, Mohsen Saleh ^j   Kattamis, Antonis ^k   Smith, Gillian ^a   Habr, Dany ^l   Domokos, Gabor ^l   Roubert, Bernard ^l   Taher, Ali ^m  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^e CAIRO UNIVERSITY   (Egypt)

^f EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^g HOSPITAL KUALA LUMPUR   (Malaysia)

^h CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

ⁱ MAHIDOL UNIVERSITY   (Thailand)

^j AIN SHAMS UNIVERSITY   (Egypt)

^k UNIVERSITY OF ATHENS   (Greece)

^l NOVARTIS PHARMA AG   (Switzerland)

^m AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

more..

Author keywords

thalassemia major; Cardiac iron overload; Deferasirox; Iron chelation; Myocardial T2*

Indexed keywords

DEFERASIROX; FERRITIN; IRON;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; HEART FUNCTION; HEART MUSCLE; HUMAN; INCIDENCE; IRON OVERLOAD; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHRITIS; PROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; BENZOIC ACIDS; BETA-THALASSEMIA; CHILD; FEMALE; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; PROGNOSIS; PROSPECTIVE STUDIES; TRIAZOLES; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 78650996705     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.031468     Document Type: Article

References (22)

1. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, et al. Survival and causes of death in thalassaemia major. Lancet. 1989;2(8653):27-30.
2. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-93.
3. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008; 10(1):42.
4. Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. Hemoglobin. 2006;30(2):219-27.
5. Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2004;103(5):1934-6.
6. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22 (23):2171-9.
7. Pennell DJ. T2* magnetic resonance and myocardial iron in thalassemia. Ann NY Acad Sci. 2005;1054:373-8.
8. Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120(20):1961-8.
9. Carpenter JP, He T, Kirk P. Calibration of myocardial iron concentration against T2- star cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2009;11(Suppl 1):abst P224.
10. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107:3738-44.
11. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(4):1876-84.
12. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson. 2008;10(1): 12.
13. Pennell DJ, Porter JB, Cappellini MD, El- Beshlawy A, Chan LL, Aydinok Y, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood. 2010;115(12):2364-71.
14. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105(2):855-61.
15. Lal A, Sweeters N, Herz M, Foote D, Neumayr L, Kurio G, et al. Safety of combined chelation therapy with deferasirox and deferoxamine in transfusion-dependent thalassemia. Blood. 2009;114(22):abst 2021.
16. Wood JC, Kang BP, Thompson A, Giardina P, Harmatz P, Glynos T, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood. 2010;116(4):537-43.
17. Kakhlon O, Manning H, Breuer W, Melamed-Book N, Lu C, Cortopassi G, et al. Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation. Blood. 2008;112(13):5219-27.
18. Pennell DJ, Porter J, Cappellini MD, et al. Continued improvement in cardiac T2* with deferasirox treatment over 2 years: Results from the extension of EPIC cardiac substudy in beta-thalassaemia patients with myocardial siderosis [abstract]. Haematologica. 2010;95 (Suppl 2):abst 0498.
19. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous ß-thalassemia. N Engl J Med. 1994; 331(9):574-8.
20. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89(3):739-61.
21. Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood. 2003;101(11):4632-9.
22. Taher A, Cappellini MD, Vichinsky E, Galanello R, Piga A, Lawniczek T, et al. Efficacy and safety of deferasirox doses of>30 mg/kg per d in patients with transfusion- dependent anaemia and iron overload. Br J Haematol. 2009;147(5):752-9.